Literature DB >> 15007559

[Giant cell tumor of bone with rapid malignant course].

M R Lachat1, M Weber, M D Cserhati, H P Honegger, A R von Hochstetter.   

Abstract

The case of a 28-year-old male patient with a locally aggressive lesion of the distal tibia is presented. Following the diagnosis of giant cell tumor of bone (GCT) on biopsy and curettage, a rapid malignant course was observed with recurrence 2.5 months later. Multiple metastases appeared 6 months after initial presentation. Following initial chemotherapy according to the COSS protocol and later with carboplatin and VP-16, therapy was changed to Adriamycin and later gemcitabine due to progressive disease. Good palliation was achieved, and the patient felt well with less shortness of breath on exertion and was ambulatory with walking aids. The malignant nature of the tumor was not detected in the initial pathologic examinations. Review of the pathologic material provided histologic clues permitting the diagnosis of a primary malignant GCT with a fibrohistiocytic/fibrosarcomatous component. Malignancy in a giant cell tumor is a much debated diagnostic dilemma when a frank sarcomatous component is lacking. Cytologic atypias and flame-like tufts of infiltration of soft tissue are important clues. Surgical treatment should be commensurate. Monotherapy with Adriamycin or gemcitabine can be considered in order to inhibit the disease progression.

Entities:  

Mesh:

Year:  2004        PMID: 15007559     DOI: 10.1007/s00132-003-0554-7

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.087


  16 in total

1.  Recurrent giant-cell tumor with metaplasia and malignant change, not associated with radiotherapy. A case report.

Authors:  F L Hefti; A Gächter; W Remagen; A Nidecker
Journal:  J Bone Joint Surg Am       Date:  1992-07       Impact factor: 5.284

2.  Late malignant transformation of a benign giant-cell tumor of bone. A case report.

Authors:  R J Sakkers; R O van der Heul; H M Kroon; A H Taminiau; P C Hogendoorn
Journal:  J Bone Joint Surg Am       Date:  1997-02       Impact factor: 5.284

3.  Giant-cell tumour of bone metastasising to the lungs. A long-term follow-up.

Authors:  K A Siebenrock; K K Unni; M G Rock
Journal:  J Bone Joint Surg Br       Date:  1998-01

Review 4.  De novo malignant transformation of giant cell tumor of bone.

Authors:  T Marui; T Yamamoto; H Yoshihara; M Kurosaka; K Mizuno; T Akamatsu
Journal:  Skeletal Radiol       Date:  2001-02       Impact factor: 2.199

Review 5.  Primary malignant giant cell tumor of bone: a study of eight cases and review of the literature.

Authors:  A G Nascimento; A G Huvos; R C Marcove
Journal:  Cancer       Date:  1979-10       Impact factor: 6.860

6.  Primary malignant giant cell tumor of bone: "dedifferentiated" giant cell tumor.

Authors:  J M Meis; H D Dorfman; S D Nathanson; A M Haggar; K K Wu
Journal:  Mod Pathol       Date:  1989-09       Impact factor: 7.842

7.  Giant-cell tumor of bone with pulmonary metastases.

Authors:  F Bertoni; D Present; W F Enneking
Journal:  J Bone Joint Surg Am       Date:  1985-07       Impact factor: 5.284

8.  Secondary malignant giant-cell tumor of bone. Clinicopathological assessment of nineteen patients.

Authors:  M G Rock; F H Sim; K K Unni; G A Witrak; F J Frassica; M F Schray; J W Beabout; D C Dahlin
Journal:  J Bone Joint Surg Am       Date:  1986-09       Impact factor: 5.284

9.  Postradiation osteogenic sarcoma of bone and soft tissues. A clinicopathologic study of 66 patients.

Authors:  A G Huvos; H Q Woodard; W G Cahan; N L Higinbotham; F W Stewart; A Butler; S S Bretsky
Journal:  Cancer       Date:  1985-03-15       Impact factor: 6.860

10.  Giant-cell tumor of bone.

Authors:  M Campanacci; N Baldini; S Boriani; A Sudanese
Journal:  J Bone Joint Surg Am       Date:  1987-01       Impact factor: 5.284

View more
  1 in total

Review 1.  Giant cell tumor of the uterus: case report and response to chemotherapy.

Authors:  Keith M Skubitz; J Carlos Manivel
Journal:  BMC Cancer       Date:  2007-03-14       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.